Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.

A new study found that walking just a few thousand steps daily can significantly delay Alzheimer’s symptoms.

Good morning, everyone, and welcome, everyone, to the Prelude Therapeutics Investor Conference Call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now ...

2025 Revenue Guidance -- Management expects full-year revenue of $30 million to $40 million, with Q4 guidance of $5 million ...

"Completed numerous design reviews." Former SpaceX engineers develop small nuclear reactors that could revolutionize energy ...

Humacyte, Inc. ( HUMA) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Good morning, ladies and gentlemen, and welcome to the Humacyte's Third Quarter Results Conference Call. [Operator ...

Researchers have uncovered surprising evidence that anxiety may be controlled not by neurons but by two dueling groups of ...

This study provides valuable insights into the role of the NF-kB and IKK signaling pathways in γδ T cell development and survival, using robust genetic mouse models. While the research is ...

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the ...

We applied swim flume-mediated exercise during zebrafish caudal fin regeneration to explore mechanical loading impacts on a robust model of organ regeneration. Exercise initiated during but not after ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Replacing APOE4 with APOE2 in adult mice rapidly reshapes brain lipids and gene expression, even after development is ...